Development of SARS-CoV-2 entry antivirals

Meiyue Dong; Jazmin M Galvan Achi; Ruikun Du; Lijun Rong; Qinghua Cui

doi:10.1016/j.cellin.2023.100144

Development of SARS-CoV-2 entry antivirals

Cell Insight. 2024 Jan 30;3(1):100144. doi: 10.1016/j.cellin.2023.100144. eCollection 2024 Feb.

Authors

Meiyue Dong¹, Jazmin M Galvan Achi², Ruikun Du^{1

3}, Lijun Rong², Qinghua Cui^{1

3}

Affiliations

¹ Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, China.
² Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL60612, USA.
³ Qingdao Academy of Chinese Medical Sciences, Shandong University of Traditional Chinese Medicine, Qingdao, Shandong, 266122, China.

Abstract

The global outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatened human health and public safety. The development of anti-SARS-CoV-2 therapies have been essential to curb the spread of SARS-CoV-2. Particularly, antivirals targeting viral entry have become an attractive target for the development of anti-SARS-CoV-2 therapies. In this review, we elucidate the mechanism of SARS-CoV-2 viral entry and summarize the development of antiviral inhibitors targeting viral entry. Moreover, we speculate upon future directions toward more potent inhibitors of SARS-CoV-2 entry. This study is expected to provide novel insights for the efficient discovery of promising candidate drugs against the entry of SARS-CoV-2, and contribute to the development of broad-spectrum anti-coronavirus drugs.

Keywords: Antiviral inhibitors; Cell entry; SARS-CoV-2; SARS-CoV-2 variants.

Publication types

Review